<unk> , sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50mg<unk> , 200mg<unk> , and 25mg tenofovir<unk> . It was approved for use in the United States in February 2018, and for use in the European Union in June 2018.
Bictegravir/emtricitabine/tenofovir alafenamide
Doravirine/lamivudine/tenofovir
Dolutegravir/lamivudine/tenofovir
Lamivudine/tenofovir
Atazanavir/ritonavir
Abacavir/lamivudine/zidovudine
Emtricitabine/rilpivirine/tenofovir
Abacavir/lamivudine